Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer


Turan N., Benekli M., Dane F., Unal O. U., Kara H. V., Koca D., ...Daha Fazla

THORACIC CANCER, cilt.5, sa.5, ss.398-404, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 5 Sayı: 5
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1111/1759-7714.12107
  • Dergi Adı: THORACIC CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.398-404
  • Anahtar Kelimeler: Adjuvant chemotherapy, bevacizumab, colorectal cancer, pulmonary metastasectomy, III COLON-CANCER, RANDOMIZED CONTROLLED-TRIAL, LUNG METASTASECTOMY, PHASE-III, PROGNOSTIC-FACTORS, K-RAS, BOLUS FLUOROURACIL, MUTATION STATUS, STAGE-II, OXALIPLATIN
  • Gazi Üniversitesi Adresli: Evet

Özet

Introduction: We investigated the impact of modern chemotherapy regimens and bevacizumab following pulmonary metastasectomy (PM) from metastatic colorectal cancer (CRC).